Professor, Department of Neurology, Center for Neurodegeneration & Neurotherapeutics & Center for Genomic & Computational Biology
Duke University Medical Center
Dr. Chiba-Falek is a Professor in the Department of Neurology at Duke University School of Medicine and a faculty in the Bryan Alzheimer's Disease Research Center (ADRC). She is also a faculty member in the Duke’s Center for Genomic and Computational Biology (GCB), the Duke Center for Neurodegeneration & Neurotherapeutics, and in the Division of Human Genetics. After receiving her PhD from the Department of Genetics at the Hebrew University in Jerusalem in 1999, she undertook a post-doctoral position at the National Human Genome Research Institute with Dr. Robert Nussbaum. She joined the faculty at Duke University in 2007. Dr. Chiba-Falek major interest is in the understanding of the genetic complexity and genomic architecture of age-related neurodegenerative diseases (NDDs), in particular Alzheimer’s disease, related dementia, and Lewy body spectrum disorders. Her research program has translational aspects to inform clinical studies, and for the development of new genetic biomarkers and therapeutic targets. She has recently embarked on efforts to translate basic research findings regarding gene dysregulation mechanisms underlying NDDs to ‘smart drug’ discovery based on CRISPR/dCas9 technology. She has published over 50 articles in peer-reviewed journals. Her research has been continuously funded by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), as well as institutional and private foundations. Dr. Chiba-Falek was a recipient of the Ellison New Scholar in Aging Award in 2008, the Holland Trice Scholar Award in 2016, and the Kahn Neurotechnology Development Award in 2017.
Senior Scientist, Market Enabling Technologies & CDx, Experimental Medicine
Andrea Camperi is a Senior Scientist in the Market Enabling Technologies and Companion Diagnostics team, within the Experimental Medicine division at Merck KGaA, Darmstadt. He is currently responsible for the evaluation and scouting of new biomarker platforms and he supports CDx and patient enrollment strategies for Merck drug development programs. He received a PhD in Experimental Medicine and Therapy from the University of Turin in 2014, where he had previously obtained a master's degree in Biomolecular Sciences in 2008.
Chief Scientific Officer
After starting her career in the field of molecular biology and tissue culture, Madhu went on to focus on molecular histopathology research, supporting biomarker development for Barrett's Oesophagus at the MRC cancer cell unit in Cambridge. Whilst at the MRC toxicology unit, University of Cambridge, Madhu developed on in-situ hybridization assays coupled with multiplex IHC to study translation dysregulation in lung adenocarcinoma, with specific focus on quantitative analysis of translation initiation factors such as eIF4 complex. Madhu recently joined BioIVT’s PHASEZERO Research Services team to develop multiplex IHC assays to support target and biomarker validation. Madhu has a PhD from the University of Calcutta, India.
Chief Medical Officer
Managing Director, Marketing
Head, Radiation Oncology UM, Chairman, Precision Oncology Group, D-Lab & M-Lab Group, Chief Scientific Advisor
Philippe Lambin is a Clinician, Radiation Oncologist and pioneer in translational research with a focus on hypoxia and Decision Support Systems. He has a PhD in Radiation Biology. He is a “ERC advanced & ERC PoC grant laureate” from 2016 & 2018 and he is co-author of more than 450 peer reviewed scientific papers (Hirsch Index ) Google scholar: 86), co-inventor of more than 18 patents (filed or submitted) of which 5 are in the (pre)commercialization phase and (co) promoter of more than 50 completed PhD’s (2 with cum laude). Moreover, Prof. P. Lambin has extensive experience with clinical trials. He was one of the international experts in the Flims workshop “Methods in Clinical Cancer Research organised jointly by the FECS, AACR and ASCO and he is leading several clinical trials. He has been also a member of the scientific advisory committee of KWF (the main Dutch funding body in cancer research), NKI-AVL, Institut Curie, Royal Marsden, CERN and of the advice committee on protontherapy of CVZ (the Dutch medical insurance). He is currently involved in several successful European grants (e.g. CDPT, Biocare, Euroxy, Metoxia, euroCAT, Eureca, Artforce, Radiate, Requite, BD2decide, ImmunoSABR, PREDICT…) and two NIH grant from the US (“Radiomics”). His main areas of interest are directed towards translational research in Oncology with a specific focus on tumour hypoxia, functional imaging (CT-PET), lung and head and neck cancer. More recently his interests have been directed towards the development of a “treatment decision support system” based on multiparametric databases containing clinical, imaging, biological and therapeutic information, and taking into account patient preferences. He is one of the inventor of “Radiomics” and “Distributed learning” a revolutionary Big Data approach for health care.
Head, Hematology & Oncology Pipeline & CDx, Global Market Access & Pricing
Head, Enabling Technologies Global Business Development & Alliance Management
Executive Vice President
Visiting Scientist & Cancer Genomics Consultant
Sanger Institute & NHS
Philip is a physician scientist and precision oncology specialist who operates across the commercial, academic and healthcare sectors. Current projects include clinical implementation of cancer genomics, biomarker discovery and early phase clinical trials, underpinned by a portfolio of relevant academic research.
Associate Director, NICE Diagnostics Assessment Programme
Sarah is the Associate Director of the NICE Diagnostics Assessment programme and has a keen interest in the value of diagnostics to patients and the healthcare system. She is leading on work in genomics, precision medicine and AMR diagnostic technologies at NICE, and is also Chair of the Equality Expert Group for the NICE Centre of Health Technology Evaluation. Prior to joining NICE, Sarah completed a PhD in Biochemistry with the University of Manchester and GlaxoSmithKline, and then worked in research and development at AstraZeneca.
Global CDx Discipline Director
Director, Biomarkers & Companion Diagnostics
Christophe Le Tourneau
Head, Department of Drug Development & Innovation
Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at the Versailles-Saint-Quentin-en-Yvelines University. He is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007. He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology. He ran the first randomized precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advances cancer. He has published 140+ peer-reviewed papers in international journals.
CSO & CEO
Senior Vice President, Commercial Operations
Head, Bioinformatics Research Services
Dr Loukas Moutsianas is the Head of Bioinformatics Research Services at Genomics England. A statistical geneticist by background, Loukas has extensive research experience in the genomics of complex traits, and immune-mediated disease in particular, and has contributed to several high impact papers in his field. Loukas obtained his D.Phil. in Statistical Genetics & Bioinformatics from the University of Oxford and had spells as a research scientist at the University of Oxford and the Wellcome Sanger Institute. He holds a joint appointment with Queen Mary University, where he is a senior lecturer at the William Harvey Research Institute.
Clinical Senior Lecturer, Consultant Upper GI & General Surgeon
Imperial College London
Christopher Peters went to medical school in Leeds and after completing basic surgical training moved to Cambridge to carry out a PhD with Professor Rebecca Fitzgerald. During his PhD he developed a four gene signature to predict outcome in oesophageal adenocarcinoma which was validated in 371 independent cases. He also set up the OCCAMS collaboration which went on to be selected to run the International Cancer Genome Consortium's Whole Genome sequencing project in oesophageal adenocarcinoma. OCCAMS has ongoing CRUK funding and has now recruited in excess of 3000 patients. After moving to London to complete his higher surgical training he was appointed as a Clinical Senior Lecturer and Consultant Upper GI surgeon at Imperial College London with a specialist interest in Biomarkers. His academic interest is molecular and clinical predictors of outcome in Oesophageal adenocarcinoma, and in particular developing ways of combining the two to improve stratification of patients. As the Biomarker lead for the NIHR London IVD Co-operative he also has a programme built around trying to better understand which Biomarkers are likely to achieve clinical adoption- aiming to bridge the gap between the millions spent on Biomarker discovery and validation and the handful that achieve clinical success.
Senior Director, Companion Diagnostics, Business Development
Senior Director, Diagnostics Partnerships
Global Head, Biomarkers & Clinical Bioanalysis
Innovation & Precision Medicine Lead
Karen joined Innovate UK, part of UK Research and Innovation, in 2017 as Innovation Lead for Precision Medicine. Karen is responsible for delivering the strategy to fund and support UK businesses towards commercial development of Precision Medicine technologies. Innovate UK is a non-departmental public body which is the prime channel through which the Government incentivises innovation in business. Karen has over 20 years of experience in leading collaborative R&D and in the translation of innovation into business opportunity from various technology platforms and therapeutic areas. This includes over 9 years at Pfizer driving the implementation of emerging therapeutics such as RNAi as well as being a founding member of The Research Network Ltd., a virtual drug discovery company. More recently Karen has led multidisciplinary consortia involving Biotech, NHS, and academic stakeholders to develop a robust clinical diagnostic for non-invasive whole-genome profiling of cancerous tumours. With Innovate UK support, multiple opportunities were evaluated for commercialization and integration of the platform into the NHS. Karen holds a PhD in Molecular Genetics and a BSc in Biochemistry & Genetics from the University of Nottingham.
Vice President MHS, Global IVD
Technical & Clinical Lead
Head, Research & Services
Scleroderma & Reynaud's UK
Fatima Ann Sulaiman is the Head of Research and Services at Scleroderma and Raynaud’s UK (SRUK). SRUK is a patient focused organisation which funds research into scleroderma, a rare orphan auto immune condition. She is leading on the development and implementation of an innovative research strategy which focuses on working collaboratively across industry in order to deliver benefits to patients sooner. A key area of focus is precision medicine and the clinical development of biomarkers which represent large unmet needs for rare disease patients. Previously, she was a senior manager at Cancer Research UK, one of the largest funders of scientific research in the UK. Prior to this, she complete a PhD from the National Institute for Medical Research (now part of the Francis Crick Institute).
Senior Director, Global Regulatory Affairs, Clinical & Compliance
Thermo Fisher Scientific
Kelli L. Tanzella, Ph.D. Sr. Director Global Regulatory Affairs, Clinical, & Compliance for Life Sciences Solution Group (LSG) at Thermo Fisher Scientific, Inc., has over 25 years’ experience in quality and regulatory requirements in both the pharmaceutical and medical device industries. She has been with Thermo Fisher Scientific for 17 years in Regulatory Affairs with increasing levels of responsibility and currently leads the global regulatory and clinical affairs team within the Life Sciences Group at Thermo Fisher. She has expertise in pre-market approvals relevant to both the pharmaceutical and medical device (IVD) industries and post-market surveillance activities. In addition, she has extensive experience in the development and implementation of regulatory strategies to enable business opportunities in NGS, CDx and Cell Therapy solutions. Kelli received a Bachelor’s of Science in Biology from Niagara University and went on to receive a Master’s of Science in Health Services Administration from D’Youville College and a Doctorate in Health Services Administration from Kennedy Western University.
Vice President, Companion Diagnostics
Director & Head, Clinical Trials Biosample Management
Head, Internal Product Management
Almac Diagnostic Services